Back to Newsroom

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

CALGARY, June 22, 2015 /CNW/ – Resverlogix Corp. (TSX: RVX) today announced that following recent meetings with various European regulatory bodies, the first confirmation for our Phase 3 clinical plan has officially been received. A further regulatory and protocol design update will be provided to the market post the approval of additional regulatory bodies and the launch of our planned Phase 3 clinical trial entitled BETonMACE.

Click here to read more